168. Cancer Discov. 2018 Apr;8(4):OF8. doi: 10.1158/2159-8290.CD-RW2018-022. Epub 2018Feb 9.AR Inhibition Achieves Responses in AR+ Triple-Negative Breast Cancer.[No authors listed]The AR inhibitor enzalutamide achieved responses in patients with advanced TNBCin a phase II trial.Â©2018 American Association for Cancer Research.DOI: 10.1158/2159-8290.CD-RW2018-022 PMID: 29439153 